Form 4: Nektar R&D Chief Sells Shares Under 10b5-1 Plan

Nektar Therapeutics' Chief R&D Officer, Jonathan Zalevsky, sold 3,867 shares of common stock for a weighted average price of $35.67 per share under a pre-arranged trading plan.

Summary

• Jonathan Zalevsky, Chief R&D Officer of Nektar Therapeutics (NKTR), disposed of 3,867 shares of common stock.
• The transaction occurred on January 20, 2026.
• The shares were sold at a weighted average price of $35.67 per share, with individual trades ranging from $35.17 to $36.23.
• This sale was executed pursuant to a Rule 10b5-1 trading plan adopted on May 16, 2025.
• Following the transaction, Jonathan Zalevsky directly owns 21,354 shares of Nektar Therapeutics common stock.

Sentiment

Score: 5

Explanation: A neutral score as this is a pre-scheduled insider sale under a 10b5-1 plan, which is a routine event and does not typically signal a change in company fundamentals or management's confidence.

Future Outlook

NA

Industry Context

This is a routine insider transaction filing for a biotechnology company. Such sales under a Rule 10b5-1 plan are common for executives to manage personal finances and diversify holdings without being accused of trading on material non-public information. It does not inherently reflect a change in the company's operational or strategic direction.

Stakeholder Impact

• Shareholders may note a slight reduction in insider ownership, though the pre-planned nature of the sale mitigates concerns about management's confidence in the company's future.

Key Dates

Recommendation

This Form 4 reports a routine, pre-scheduled insider stock sale by a Chief R&D Officer under a Rule 10b5-1 plan. Such transactions are common for executive financial planning and diversification and do not typically indicate a change in the company's fundamental prospects or management's long-term view. Therefore, it provides no new information to warrant a change in investment recommendation, maintaining a 'hold' stance based on existing company fundamentals.

Keywords

Nektar Therapeutics, NKTR, Insider Trading, Form 4, Jonathan Zalevsky, Stock Sale, Rule 10b5-1, Chief R&D Officer